MA backs MSD concerns over Zinplava rejection

July 8, 2020 Latest News

This is a preview of subscriber content

Subscribe now to continue reading.

Medicines Australia has backed concerns over the decision-making process for MSD's ZINPLAVA while the FDA advised against the current use of the intervention the PBAC used as the significant basis for the rejection. …

Subscribe now to continue reading.

Latest Video

Georgia Forrest

Trump administration launches third round of price negotiations, including the first renegotiation
January 28, 2026 - Latest News
Obesity medicines, the limits of the PBS, and the test of policy imagination
January 28, 2026 - Latest News
Americans pay a much lower share of health costs than we do in Australia
January 27, 2026 - Latest News
New digital health reforms to give Australians a more complete medicines history
January 28, 2026 - Latest News
Australia’s health information ecosystem is very full, but do the best voices dominate?
January 27, 2026 - Latest News

MA backs MSD concerns over Zinplava rejection

This is a preview of subscriber content

Latest Video

Most Read

Trump administration launches third round of price negotiations, including the first renegotiation

Obesity medicines, the limits of the PBS, and the test of policy imagination

Americans pay a much lower share of health costs than we do in Australia

New digital health reforms to give Australians a more complete medicines history

Australia’s health information ecosystem is very full, but do the best voices dominate?

New Stories

International HTA Collaboration continues as global pricing pressures evolve

How an Australian Campaign Is tackling the silent epidemic of heart and kidney disease

ARCS warns workforce gaps threaten returns on clinical trials reform

AstraZeneca appoints new country president as Ben McDonald transitions to global role

Why do some appear so uncomfortable with this group of people getting help?

New digital health reforms to give Australians a more complete medicines history

Peer-reviewed validation strengthens Paradigm’s osteoarthritis program

Sign In

MA backs MSD concerns over Zinplava rejection

This is a preview of subscriber content

Latest Video

Most Read

Trump administration launches third round of price negotiations, including the first renegotiation

Obesity medicines, the limits of the PBS, and the test of policy imagination

Americans pay a much lower share of health costs than we do in Australia

New digital health reforms to give Australians a more complete medicines history

Australia’s health information ecosystem is very full, but do the best voices dominate?

Follow Us

New Stories

International HTA Collaboration continues as global pricing pressures evolve

How an Australian Campaign Is tackling the silent epidemic of heart and kidney disease

ARCS warns workforce gaps threaten returns on clinical trials reform

AstraZeneca appoints new country president as Ben McDonald transitions to global role

Why do some appear so uncomfortable with this group of people getting help?

New digital health reforms to give Australians a more complete medicines history

Peer-reviewed validation strengthens Paradigm’s osteoarthritis program